A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

NCT06339008 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Perennial Allergic Rhinitis (PAR)

Interventions

DRUG: LY3650150
DRUG: Placebo
DRUG: Standard therapy for INCS

Sponsor

Eli Lilly and Company